NKGen Biotech, Inc.

Graf Acquisition Corp. IV, trading on Nasdaq under the ticker GFOR, is a special purpose acquisition company sponsored by Graf Acquisition Holdings that completed its initial public offering in 2021, targeting the healthcare and life sciences sectors. As of its May 2023 quarterly filing with the SEC, the company was pursuing a proposed business combination with NKGen Biotech, Inc., a clinical-stage biopharmaceutical firm developing natural killer cell-based immunotherapies for neurodegenerative diseases and oncology indications. The 10-Q captures the SPAC's operational and financial position during the period leading up to the anticipated de-SPAC merger with NKGen Biotech. For complete filing histories, sponsor profiles, and deal-stage tracking on GFOR and the broader SPAC universe, sign up for full data access at SpacDesk.